Navigation Links
Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke
Date:5/15/2008

he risk of coronary events in patients with stroke or TIA. (Risk of coronary events in patients with stroke or TIA: Two-year follow-up data from the REduction of Atherothrombosis for Continued Health (REACH) Registry: Touze E, Rother J, Alberts MJ, Goto S, Hill MD, Aichner F, Steg PG, Bhatt DL, Mas JL, on behalf of the REACH Registry Investigators). Whereas the incidence rates of MI and nonstroke vascular death are only about 1% per year, the risk rises in patients with additional CAD to 2 to 2.5% again underlining the increased risk of polyvascular disease.

Objectives and scope of REACH

The overall aim of the REACH Registry is to improve the assessment and management of stroke, heart attack and associated risk factors for atherothrombosis. It is the largest and most geographically extensive global registry of patients at risk of atherothrombosis, having recruited over 68,000 patients in 44 countries, covering six regions -- Latin America, Asia, the Middle East, Australia, Europe and North America -- and involving over 5,000 physician investigators.(4,5)

The REACH Registry includes a broad spectrum of patients with atherothrombosis -- documenting the health status and treatment of people at risk of atherothrombosis; monitoring how they are affected; and measuring the burden of the disease. Patients included in the REACH Registry either have several of the risk factors that can lead to atherothrombosis, such as, high cholesterol, high blood pressure, smoking, and diabetes, or have a previous history of heart attack, stroke or PAD. Participation in the REACH Registry is strictly voluntary.

In addition, the REACH Registry is based in a real-life setting and seeks to increase overall understanding of atherothrombotic disease across several medical specialties (cardiology, neurology, internal medicine, vascular medicine and office-based primary care physicians), which allows for a more thorough assessment of the real-world burden of the diseas
'/>"/>

SOURCE REACH Registry
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
2. Biomatricas RNAstable(TM) Stabilizes RNA at Room Temperature
3. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
4. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
5. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
10. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... - EastMed Inc., the medical manufacturing company that caters ... clearance to market its flagship product, uresta(TM) Continence Care, ... to get the official word from the FDA," said ... (TM) Continence Care offers an innovative and cost-effective option ...
... Nov. 25 /PRNewswire/ - Aegera Therapeutics Inc. today announced ... the XIAP antisense oligonucleotide, AEG35156, will be highlighted in ... the American Society of Hematology (ASH) in San Francisco, ... presentation is entitled "Phase I/II Trial of the XIAP ...
... a business unit of DSM Pharmaceutical Products, and Dutch,biotechnology company ... today announced that Hungary-based Gedeon Richter Plc. signed a,commercial license ... the PER.C6(R) platform. , ... About PER.C6(R) technology , ...
Cached Biology Technology:Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 2Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 3DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 2DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 3DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 4
(Date:4/14/2014)... David Kisailus, the Winston Chung Endowed Chair ... Riverside,s Bourns College of Engineering, has been named ... scientists selected by the advisory board of the ... Sciences and organizers of the Kavli/National Academy of ... Foundation, which is based in Oxnard, supports scientific ...
(Date:4/14/2014)... you feel when an elevator zips you up multiple floors ... elevator carried you all the way up to the top ... , That,s similar to what many fish experience when they ... the change in pressure is simply too big, too fast, ... article in the March issue of the journal Fisheries ...
(Date:4/14/2014)... Chicago,s Field Museum and international collaborators have reconstructed the ... the New World tropics, the region of the Earth ... nuclear DNA sequences uncovered three species new to science, ... Since 1960, when modern studies on this group began, ... 22. The newest additions were described in a ...
Breaking Biology News(10 mins):Professor receives young scientist honor 2Making dams safer for fish around the world 2Making dams safer for fish around the world 3Making dams safer for fish around the world 4Making dams safer for fish around the world 5Three new species of yellow-shouldered bats discovered in museum collections 2Three new species of yellow-shouldered bats discovered in museum collections 3
... to new research funded by the Economic and Social ... Open University, led by Professor Andy Lane, has taken ... not those mainly involved in organic growing - ... and the food industry regard GM, but this is ...
... is the ultimate destination for anyone interested in natural history ... broadly about our responsibilities to all life on Earth. Thats ... and the Environment at The University of Nottingham, who has ... Observer for the International Association of Antarctica Tour Operators (IAATO). ...
... Now think of bacteria eating rock below the ocean ... 15,000 feet underwater" With a $3.9 million grant ... Katrina Edwards will lead a first-of-its-kind drilling expedition to ... which live on chemical reactions with rock and water, ...
Cached Biology News:What farmers think about GM crops 2Observing sustainable tourism in Antarctica 2Observing sustainable tourism in Antarctica 3USC awarded $3.9M for lab under the sea 2
In plasmid or lambda vector. Please inquire for more details!...
NANS Immunogen: NANS (NP_061819, 260 a.a. ~ 360 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Anti-Mouse D011.10 TCR, Biotin (Clone KJ1-26) (mouse IgG2a)...
... SARA ( Abpromise for all tested ... peptide: PVPKEMEQPV QTEEEDVELP conjugated to KLH, corresponding ... (Drosophila melanogaster) SARA. Conserved sequence unique ... ID: 9372 Swiss ...
Biology Products: